Advertising Archives

Currently viewing the category: "Advertising"

FTC’s Ban of “Biodegradable” Claims in the ECM Case Threatens an Expansion of FTC Authority (Case Comment)

By Peter Arhangelsky On October 22, 2015 · Add Comment

Read Full Article →

FTC Bans “Biodegradable” on Products

By Peter Arhangelsky On October 21, 2015 · Add Comment

Read Full Article →

Biodegradable Plastics Claim Upheld Against FTC Challenge in Precedent Setting ECM BioFilm’s Case

By Peter Arhangelsky On February 6, 2015 · Add Comment

Read Full Article →

D.C. Circuit: FTC’s Two RCT Requirement Violates the First Amendment

By eawerbuch On February 2, 2015 · Add Comment

Read Full Article →

Experts Recap Oral Arguments Before the Supreme Court in POM v. Coke

By Peter Arhangelsky On April 22, 2014 · Add Comment

Read Full Article →

Attorney Peter Arhangelsky Comments on Upcoming POM v. Coke Decision

By Peter Arhangelsky On April 18, 2014 · Add Comment

Read Full Article →

Be Careful What You Link To

By bkennedy On May 13, 2013 · Add Comment

Read Full Article →

How FDA and EFSA Prior Restraints Defeat Government Objectives and Foster Fraud and Deception

By jemord On May 13, 2013 · Add Comment

Read Full Article →

FDA PRESUMES ITSELF OMNISCIENT AND CONSUMERS IGNORANT

By jemord On May 6, 2013 · Add Comment

Read Full Article →

FDA Dislikes Supplement Company’s Facebook “Like”

By bkennedy On April 1, 2013 · Add Comment

Read Full Article →

FTC’s POM Wonderful Decision Will Dumb Down the Marketplace

By bkennedy On February 25, 2013 · Add Comment

Read Full Article →

The Rule of Innocent Construction

By jemord On January 4, 2013 · 3 Comments

Read Full Article →

The FDA’s and FTC’s Reliance On Randomized Clinical Trials For Dietary Ingredients Is Impractical and Unethical

By Peter Arhangelsky On December 20, 2012 · Add Comment

Read Full Article →

Current FDA Appears Not to Follow FDA’s Informal Two-Click Policy

By bkennedy On December 18, 2012 · Add Comment

Read Full Article →

Second Circuit Invalidates FDA Regulation of Drug Advertising on First Amendment Grounds in Landmark Decision that Portends Far Reaching Effects

By Peter Arhangelsky On December 5, 2012 · 4 Comments

Read Full Article →

Categories
Archives
Calendar

June 2023

M T W T F S S

« Aug

1 2 3 4

5 6 7 8 9 10 11

12 13 14 15 16 17 18

19 20 21 22 23 24 25

26 27 28 29 30
Meta
- Log in
- Entries (RSS)

FTC’s Ban of “Biodegradable” Claims in the ECM Case Threatens an Expansion of FTC Authority (Case Comment)

FTC Bans “Biodegradable” on Products

Biodegradable Plastics Claim Upheld Against FTC Challenge in Precedent Setting ECM BioFilm’s Case

D.C. Circuit: FTC’s Two RCT Requirement Violates the First Amendment

Experts Recap Oral Arguments Before the Supreme Court in POM v. Coke

Attorney Peter Arhangelsky Comments on Upcoming POM v. Coke Decision

Be Careful What You Link To

How FDA and EFSA Prior Restraints Defeat Government Objectives and Foster Fraud and Deception

FDA PRESUMES ITSELF OMNISCIENT AND CONSUMERS IGNORANT

FDA Dislikes Supplement Company’s Facebook “Like”

FTC’s POM Wonderful Decision Will Dumb Down the Marketplace

The Rule of Innocent Construction

The FDA’s and FTC’s Reliance On Randomized Clinical Trials For Dietary Ingredients Is Impractical and Unethical

Current FDA Appears Not to Follow FDA’s Informal Two-Click Policy

Second Circuit Invalidates FDA Regulation of Drug Advertising on First Amendment Grounds in Landmark Decision that Portends Far Reaching Effects

Categories

Archives

Calendar

Meta

Pages

The Latest

PRESS RELEASE: Jonathan Emord Goes Round Two with the FDA on Electroshock Devices

More

June 2023
M	T	W	T	F	S	S
« Aug
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30